ProfileGDS5678 / 1418196_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 85% 86% 87% 87% 88% 87% 88% 88% 85% 84% 86% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5638987
GSM967853U87-EV human glioblastoma xenograft - Control 26.4748185
GSM967854U87-EV human glioblastoma xenograft - Control 36.4958486
GSM967855U87-EV human glioblastoma xenograft - Control 46.83587
GSM967856U87-EV human glioblastoma xenograft - Control 56.7743487
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5699588
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4652687
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.729488
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.738188
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4199685
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.17884
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5576686
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5404586
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5585886